PRESS RELEASE: Award-winning Australian rapid HIV test featured at global AIDS conference

SYDNEY Australia, 8 July 2016 | Medical device design and development company Atomo Diagnostics will showcase its rapid diagnostic tests solutions for detection of HIV infection at the 21st International AIDS Conference from 18 to 22 July in Durban, South Africa.

The conference, also known as AIDS 2016, is the world’s largest gathering of policy makers, healthcare service providers, not-for-profit groups and individuals seeking to end the HIV/AIDS pandemic. Held annually, it typically attracts in excess of 18,000 delegates from all over the world.

Sydney-based Atomo Diagnostics has developed the world’s first lateral flow rapid HIV test that integrates the test components into a single, easy to use and affordable device.

The innovative design of the AtomoRapid™ HIV (1&2) test has been recognised internationally and the product has won several prestigious awards, including ‘Best in Show’ at the Medical Design Excellent Awards, 2014.

AtomoRapid™ HIV (1&2) eliminates the need for multiple test components, making it safe and easier to use. It’s unique design, that includes a series of interlocked user steps, helps to mitigate user errors that are common with standard rapid diagnostic test kits.

This CE-marked product was launched commercially in southern Africa in 2014, where it continues to prove popular with frontline healthcare professionals.

Atomo Diagnostics’ Group Chief Executive Officer, John Kelly, said, “We are proud to support the goals of AIDS 2016. Atomo is committed to supporting the fight against HIV/AIDS. It remains the case that there are major unmet medical needs globally for rapid, affordable, easy-to-use and accurate tests. The ability to screen accurately for HIV is crucial in determining the appropriate care and support for HIV positive adults and children.”

To support scale-up of Atomo’s business, in 2015 the company received a US$6 million investment from the US-based Global Health Investment Fund (GHIF), one of the first impact funds to focus on health. GHIF is a private investment fund structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation. The company also recently secured a A$1.8 million grant from the New South Wales Medical Device Fund 2015-2016 for the development of a self-test for rapid detection of HIV.

Atomo Diagnostics will be exhibiting at AIDS 2016 at stand #229.

For more information, please contact:
Tim Allerton or Andrew Geddes
Tel: +61 (2) 9267 4511

About HIV
The World Health Organization (WHO) estimates that in 2014 there were 36.9 million people living with HIV around the world, with a further 2 million people becoming newly infected. While the number of people newly infected with HIV is in decline in many parts of the world, it is estimated that 46% of people living with HIV do not know their HIV-positive status. Screening and diagnosis continue to play a critical role in ending the HIV/AIDS pandemic. (source:

About Atomo Diagnostics
Atomo Diagnostics is a medical device design and manufacturing company based in Sydney, Australia, with corporate offices in South Africa and the UK. The company specialises in developing rapid diagnostic tests (RDTs) that use capillary blood samples. Its refreshing, user-centered approach to design and willingness to reimagine what has gone before, has led it to produce devices that are simpler to use and help to prevent common user errors. Atomo’s all-in-one devices put the end user first and make it easy to test for a range of infectious diseases and screen for various chronic conditions.